

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	
		Filing Date	01/09/2002
		First Named Inventor	Anne Chew
		Group Art Unit	1632
		Examiner Name	Joseph Woitach
Sheet 1	of 2	Attorney Docket Number	MWH-0001US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	AKATSU T et al., "Osteoclastogenesis Inhibitory Factor Exhibits Hypocalcemic Effects in Normal Mice and in Hypercalcemic Nude Mice Carrying Tumors Associated With Humoral Hypercalcemia of Malignancy," Bone Vol. 23 (6) p 495-498 (December 1998).	
	BB	CHAMBERS TJ, "Regulation of the differentiation and function of osteoclasts," J. Pathology, September 2000 Vol 192 (1) p 4-13.	
	BC	LACEY DL et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell, 17 April 1998 Vol 93 (2) p.165-76.	
	BD	MIZUNO A et al., "Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin," Biochem. Biophys. Res. Comm., Vol 247, p 610-615 (1998).	
	BE	MORINAGA T et al., "Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis inhibitory factor," Eur. J. Biochem, 1998 Vol 254 (3) p 685-91.	
	BF	SIMONET WS et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," Cell, 18 April 1997 Vol 89 (2) p 309-19.	
	BG	TAKAHASHI N et al., "A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANSC/RANKL, regulates Osteoclast Differentiation and Function," Biochem. Biophys. Res. Comm. Vol 256, p 449-455 (1999).	
	BH	TOMOYASU A et al., "Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor," Biochem. Biophys. Res. Comm. 1998 Vol 245 (2) p. 382-7.	
	BI	YAMAGUCHI K et al., "Characterization of structural domains of human osteoclastogenesis inhibitory factor," J. Biol. Chem., 27 February 1998 Vol 273 (9) p. 5117-23.	
	BJ	YASUDA H et al., "Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," Endocrinology March 1998 Vol 139 (3) p 1329-37.	
	BK	Database Genbank, National Center for Biotechnology Information, a division of the National Library of Medicine, Accession No. U94332, May 1997.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: application of Chew, Anne et al.

for HAPLOTYPES OF THE TNFRSF11A GENE

Assistant Commissioner for Patents
Washington, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10*


(Express Mail label number is mandatory.)

(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on 1/9/02, 2002 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL594656967US addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Nathaniel D. Tjebk
(type or print name of person mailing paper)
[Signature]
Signature of person mailing

Reg. No.: 47,934
Tel. No.: 203-786-3468
Customer No.: 25106



Signature of Practitioner

Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Paerk
New Haven, CT 06511

9 - January - 2002

MWH-0001US

Transmittal of Information Disclosure Statement within 3 months